Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Journal Watch

    • 22 Accesses

    This is a preview of subscription content, log in to check access.

    References

    Reference

    1. Velo G, Moretti U. Ecopharmacovigilance for better health [editorial]. Drug Saf 2010; 33 (11): 963–8

    Reference

    1. Antoñanzas F, Gó mez P. New prescription for the Spanish drug sector: fighting against public deficit without wasting ammunition [editorial]. Pharmacoeconomics 2010; 28 (11): 977–80

    Reference

    1. Simoens S. Use of economic evaluation in decision making: evidence and recommendations for improvement. Drugs 2010; 70 (15): 1917–26

    Reference

    1. Venkatakrishnan K, Pickard MD, von Moltke LL. A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs. Clin Pharmacokinet 2010; 49 (11): 703–27

    Reference

    1. Garattini S. Evaluation of benefit-risk. Pharmacoeconomics 2010; 28 (11): 981–6

    Reference

    1. Schifilliti D, Grasso G, Conti A, et al. Anaesthetic-related neuroprotection: intravenous or inhalational Agents? CNS Drugs 2010; 24 (11): 893–907

    Reference

    1. Berger, Joseph R. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf 2010; 33 (11): 969–83

    Reference

    1. Wong WB, Carlson JJ, Thariani R, et al. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics 2010; 28 (11): 1001–13

    Reference

    1. Skaer TL, Sclar DA. Economic implications of sleep disorders. Pharmacoeconomics 2010; 28 (11): 1015–23

    Reference

    1. Ferner RE, Aronson JK. Preventability of drug-related harms — part I: a systematic review. Drug Saf 2010; 33 (11): 985–94

    Reference

    1. Cappell J, Herrmann N, Cornish S, et al. The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer’s disease. CNS Drugs 2010; 24 (11): 909–27

    Reference

    1. Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectivenesswithout head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 2010; 28 (10): 935–45

    Reference

    1. Crown WH. There’s a reason they call them dummy variables: a note on the use of structural equation techniques in comparative effectiveness research. Pharmacoeconomics 2010; 28 (10): 947–55

    Reference

    1. Caro JJ, Ishak KJ. No head-to-head trial? Simulate the missing arms. Pharmacoeconomics 2010; 28 (10): 957–67

    Reference

    1. Mullins CD, Whicher D, Reese ES, et al. Generating evidence for comparative effectiveness research using more pragmatic randomized controlled trials. Pharmacoeconomics 2010; 28 (10): 969–76

    Reference

    1. O’Neill P, Devlin NJ. An analysis of NICE’s ‘restricted’ (or ‘optimized’) decisions. Pharmacoeconomics 2010; 28 (11): 987–93

    Reference

    1. Taylor DC, Pawar V, Kruzikas D, et al. Methods of model calibration: observations from a mathematical model of cervical cancer. Pharmacoeconomics 2010 Nov 1; 28 (11): 995–1000

    Reference

    1. Aronson JK, Ferner RE. Preventability of drug-related harms — part II: proposed criteria, based on frameworks that classify adverse drug reactions. Drug Saf 2010; 33 (11): 995–1002

    Reference

    1. Svanström H, Callréus T, Hviid A. Temporal data mining for adverse events following immunization in nationwide Danish healthcare databases. Drug Saf 2010; 33 (11): 1015–25

    Reference

    1. Theóphile H, Arimone Y, Miremont-Salamé G, et al. Comparison of three methods (consensual expert judgement, algorithmic and probabilistic approaches) of causality assessment of adverse drug reactions: an assessment using reports made to a French pharmacovigilance centre. Drug Saf 2010; 33 (11): 1045–54

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Journal Watch. Pharm Med 24, 387–396 (2010). https://doi.org/10.1007/BF03256839

    Download citation